
Two major US players working to launch novel hepatitis drugs have been facing severe setbacks recently, after a tragic death in connection with clinical studies for one of the drugs, owned by Bristol-Myers Squibb.
It could open the door for Danish company Santaris, whose candidate drug Miraversen for the treatment of hepatitis C is of a very different type.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app